Evaluation study of half dose ticagrelor in the treatment of acute coronary syndrome patients after percutaneous coronary intervention
10.3969/j.issn.1673-9701.2024.31.018
- VernacularTitle:半剂量替格瑞洛对急性冠脉综合征患者经皮冠状动脉介入治疗术后的评价研究
- Author:
Miao FAN
1
;
Jiaqi YAO
Author Information
1. 宁波大学附属第一医院药学部,浙江宁波 315010
- Keywords:
Acute coronary syndrome;
Ticagrelor;
Bleeding complication;
Adverse event
- From:
China Modern Doctor
2024;62(31):76-80,89
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate clinical efficacy and safety of half dose ticagrelor in patients with acute coronary syndrome(ACS)undergoing percutaneous coronary intervention(PCI).Methods A total of 108 patients with ACS who successfully underwent PCI in the First Affiliated Hospital of Ningbo University from January 2017 to November 2019 were selected.According to the dosage of ticagrelor,the patients were divided into standard dose group(56 cases)and half dose group(52 cases).Major adverse cardiovascular and cerebrovascular event(MACCE)and safety endpoints were compared between two groups.Results There was no significant difference in the incidence of MACCE between two groups(P＞0.05).The cumulative incidence of safety endpoints in half dose group was significantly lower than that in standard dose group(9.6％vs.28.6％,P＜0.05).There was no significant difference in incidence of Bleeding Academic Research Consortium(BARC)type 2/3 bleeding between two groups(P＞0.05).However,incidence of BARC type 1 bleeding in half dose group was significantly lower than that in standard dose group(P＜0.05).Conclusion Compared with standard dose,half dose of ticagrelor can reduce the risk of bleeding and does not increase the incidence of MACCE in patients.
